Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.

Saved in:
Bibliographic Details
Title: Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
Authors: Hamaluba M; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Sang S; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Orindi B; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Njau I; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Karanja H; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Kamau N; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Gitonga JN; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Mugo D; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Wright D; Oxford Vaccine Group, University of Oxford, Oxford, England, UK., Nyagwange J; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Kutima B; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Omuoyo D; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Mwatasa M; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Ngetsa C; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Agoti C; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Cheruiyot S; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Nyaguara A; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Munene M; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Mturi N; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Oloo E; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Ochola-Oyier L; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Mumba N; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Mauncho C; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Namayi R; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Davies A; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.; Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, England, UK., Tsofa B; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Nduati EW; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Aliyan N; Ministry of Health, Nairobi, Kenya., Kasera K; Ministry of Health, Nairobi, Kenya., Etyang A; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya., Boyd A; The Jenner Institute, University of Oxford, Oxford, England, UK., Hill A; The Jenner Institute, University of Oxford, Oxford, England, UK., Gilbert S; Pandemic Sciences Institute, University of Oxford, Oxford, England, UK., Douglas A; The Jenner Institute, University of Oxford, Oxford, England, UK., Pollard A; Oxford Vaccine Group, University of Oxford, Oxford, England, UK., Bejon P; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.; Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, England, UK., Lambe T; Oxford Vaccine Group, University of Oxford, Oxford, England, UK.; Pandemic Sciences Institute, University of Oxford, Oxford, England, UK., Warimwe G; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.; Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, England, UK.
Corporate Authors: COV004 Vaccine Trial Group
Source: Wellcome open research [Wellcome Open Res] 2023 Nov 27; Vol. 8, pp. 182. Date of Electronic Publication: 2023 Nov 27 (Print Publication: 2023).
Publication Type: Journal Article
Journal Info: Publisher: Wellcome Trust Country of Publication: England NLM ID: 101696457 Publication Model: eCollection Cited Medium: Print ISSN: 2398-502X (Print) Linking ISSN: 2398502X NLM ISO Abbreviation: Wellcome Open Res Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2398-502X
DOI:10.12688/wellcomeopenres.19150.2